PIPELINE
POWERED BY
PURPOSE
Every product candidate in our pipeline represents a major step in the right direction for patients and healthcare providers. Our teams have been hard at work to grow our portfolio of acute care and oncology treatments with the goal of improving lives through innovative therapies.
OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES
RYANODEX® (dantrolene sodium) for Injectable Suspension
Learn more about RYANODEX and approved indications
Nerve-Agent Induced Brain Damage Investigational Indication
VASOPRESSIN INJECTION
PEMFEXY® (pemetrexed injection)
BELRAPZO® (bendamustine hydrochloride injection)
BENDEKA® (bendamustine hydrochloride) Injection
Learn more about BENDEKA and approved indications in the full Prescribing Information
Fulvestrant
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication
HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication
HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy Investigational Indication
